We are live on ! Find out more
BG

Bollard Group Portfolio holdings

AUM $3.29B
1-Year Est. Return 4.86%
This Fund
S&P 500
This Quarter Est. Return
+10.15%
1 Year Est. Return
-4.86%
3 Year Est. Return
+64.44%
5 Year Est. Return
+96.88%
10 Year Est. Return
+353.21%
AUM
$3.15B
AUM Growth
+$299M
Cap. Flow
+$22.4M
Cap. Flow %
0.71%
Top 10 Hldgs %
63.85%
Holding
446
New
9
Increased
234
Reduced
21
Closed
20

Top Buys

Rank Stock Value
1
MSGS icon
Madison Square Garden
MSGS
+$14.3M
2
T icon
AT&T
T
+$9.13M
3
CVX icon
Chevron
CVX
+$6.76M
4
COP icon
ConocoPhillips
COP
+$6.03M
5
BA icon
Boeing
BA
+$5.66M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$66.9M
2
OKTA icon
Okta
OKTA
+$7.43M
3
LLY icon
Eli Lilly
LLY
+$4.36M
4
RDS.A
Royal Dutch Shell PLC ADS Class A
RDS.A
+$3.04M
5
PPLI
People Inc
PPLI
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 44.54%
2 Communication Services 9.08%
3 Technology 8.64%
4 Consumer Discretionary 7.69%
5 Financials 7.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
401
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$15K ﹤0.01%
2,159
– –
OTIC
402
DELISTED
Otonomy, Inc.
OTIC
$14K ﹤0.01%
6,442
– –
KDP icon
403
Keurig Dr Pepper
KDP
$43.3B
$13K ﹤0.01%
369
+1
+0.3% +$36
DELL icon
404
Dell
DELL
$358B
$12K ﹤0.01%
235
– –
LAB icon
405
Standard BioTools
LAB
$278M
$12K ﹤0.01%
1,975
– –
UMC icon
406
United Microelectronic
UMC
$56.5B
$12K ﹤0.01%
1,250
– –
FLXN
407
DELISTED
Flexion Therapeutics, Inc.
FLXN
$12K ﹤0.01%
1,406
– –
KRRO icon
408
Korro Bio
KRRO
$204M
$11K ﹤0.01%
22
– –
EWJ icon
409
iShares MSCI Japan ETF
EWJ
$23.3B
$8K ﹤0.01%
124
+1
+0.8% +$68
ZBH icon
410
Zimmer Biomet
ZBH
$18.5B
$8K ﹤0.01%
50
– –
JNCE
411
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$7K ﹤0.01%
1,009
– –
CTMX icon
412
CytomX Therapeutics
CTMX
$604M
$5K ﹤0.01%
712
– –
HPQ icon
413
HP
HPQ
$29.5B
$5K ﹤0.01%
168
+1
+0.6% +$32
CNDT icon
414
Conduent
CNDT
$252M
$4K ﹤0.01%
530
– –
OIH icon
415
VanEck Oil Services ETF
OIH
$1.96B
$4K ﹤0.01%
16
– –
ETTX
416
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$4K ﹤0.01%
1,448
– –
OXY.WS icon
417
Occidental Petroleum Corp Warrants
OXY.WS
$35.2B
$3K ﹤0.01%
216
– –
TTOO
418
DELISTED
T2 Biosystems, Inc
TTOO
$3K ﹤0.01%
1
– –
HPE icon
419
Hewlett Packard
HPE
$75.2B
$2K ﹤0.01%
163
+2
+1% +$32
ITRM
420
DELISTED
Iterum Therapeutics
ITRM
$2K ﹤0.01%
48
– –
WAB icon
421
Wabtec
WAB
$46.7B
$2K ﹤0.01%
21
– –
MKC icon
422
McCormick & Company Non-Voting
MKC
$13.5B
$1K ﹤0.01%
12
– –
NBRV
423
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1K ﹤0.01%
40
– –
ACA icon
424
Arcosa
ACA
$7.13B
– –
-900
Closed -$59K
ASIX icon
425
AdvanSix
ASIX
$449M
– –
-212
Closed -$6K
14 15 16
17
18

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.29B AUM 6.08% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
OCM
Oribel Capital Management New York $3.29B AUM 83.82% 1-Year Est. Return
PCM
Prana Capital Management Greenwich, Connecticut $3.3B AUM 0.25% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
AIP
Atlas Infrastructure Partners London, United Kingdom $3.3B AUM 16.21% 1-Year Est. Return
ADEF
Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Bollard Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bollard Group held 446 positions worth $3.15B, up 10% from $2.85B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Bollard Group's Q2 2021 filing shows 9 new, 234 increased, 21 reduced and 20 closed positions. Its largest new stake was Vimeo: 41,444 shares worth $2.03M. The largest sale was Boston Scientific, an estimated $66.9M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 47% a quarter earlier, followed by Communication Services and Technology.

  • Bollard Group's largest Q2 2021 buy was Vimeo: 41,444 shares worth $2.03M.
  • Bollard Group added most to Madison Square Garden in Q2 2021, an estimated $14.3M increase.
  • Bollard Group's biggest Q2 2021 reduction was Boston Scientific, cutting an estimated $66.9M.
  • Bollard Group fully exited Fastly Inc in Q2 2021, selling an estimated $841K.
  • Bollard Group's ten largest holdings make up 64% of its $3.15B portfolio in Q2 2021.
  • Bollard Group opened 9 new positions and closed 20 in Q2 2021.
  • Bollard Group's portfolio value rose 10% quarter-over-quarter to $3.15B.

Based on Bollard Group's 13F filing for Q2 2021, filed 12 Aug 2021.